BioSpace News Archive

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced preliminary, unaudited ORLADEYO® (berotralstat) net revenue for the fourth quarter and full year 2023.

NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, announced, as required by Nasdaq Stock Market Rules, equity inducement awards to 10 new employees.

Xeris Biopharma Holdings, Inc. announced that on January 2, 2024, the Compensation Committee of Xeris’ Board of Directors granted restricted stock units for an aggregate of 130,000 shares of its common stock to 18 new employee under Xeris’ Inducement Equity Plan.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2023 financial and operating results on Friday, February 2, 2024, before the U.S. financial markets open.

PMV Pharmaceuticals, Inc., a precision oncology company pioneering the discovery and development of small molecule, tumor agnostic therapies targeting p53, announced key appointments across its leadership team.

BD, a leading global medical technology company, announced that it will host a live webcast of its Annual Meeting of Shareholders on Tuesday, January 23, 2024, at 1:00 p.m.

Swedish Orphan Biovitrum AB’s Chairman of the Board Bo Jesper Hansen resigns, at his own request and with immediate effect, from his position as Chairman of the Board and board member due to health reasons.

Arrowhead Pharmaceuticals, Inc. announced that on January 5, 2024, it closed the previously announced underwritten registered offering of 15,790,000 shares of its common stock, par value $0.001 per share.

Cardurion Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference.

Coya Therapeutics, Inc. today announced successful meetings with the U.S. Food and Drug Administration (FDA) following a pre-IND (Investigational New Drug) meeting and a Type C meeting intended to seek advice from the Agency to reach alignment on multiple aspects of the planned development program in support of an IND application of COYA 302 for the treatment of ALS.